ONCIMMUNE HLDNGS LS-01
Oncimmune Holdings plc, a precision medicine company, provides autoantibody biomarker profiling in immuno-oncology, autoimmune, and infectious diseases in Europe and internationally. The company offers ImmunoINSIGHTS platform, an autoantibody profiling service that provides insights to discover and validate novel biomarkers, validate drug mode of action, improve treatment responses and adverse ev… Read more
Market Cap & Net Worth: ONCIMMUNE HLDNGS LS-01 (OCY)
ONCIMMUNE HLDNGS LS-01 (F:OCY) has a market capitalization of $1.26 Million (€1.23 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #37638 globally and #4900 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ONCIMMUNE HLDNGS LS-01's stock price €0.01 by its total outstanding shares 111773000 (111.77 Million).
ONCIMMUNE HLDNGS LS-01 Market Cap History: 2021 to 2025
ONCIMMUNE HLDNGS LS-01's market capitalization history from 2021 to 2025. Data shows change from $226.02 Million to $1.26 Million (-70.67% CAGR).
ONCIMMUNE HLDNGS LS-01 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ONCIMMUNE HLDNGS LS-01's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of OCY by Market Capitalization
Companies near ONCIMMUNE HLDNGS LS-01 in the global market cap rankings as of March 19, 2026.
Key companies related to ONCIMMUNE HLDNGS LS-01 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
ONCIMMUNE HLDNGS LS-01 Historical Marketcap From 2021 to 2025
Between 2021 and today, ONCIMMUNE HLDNGS LS-01's market cap moved from $226.02 Million to $ 1.26 Million, with a yearly change of -70.67%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €1.26 Million | -93.29% |
| 2024 | €18.82 Million | -31.67% |
| 2023 | €27.54 Million | -61.60% |
| 2022 | €71.71 Million | -68.27% |
| 2021 | €226.02 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of ONCIMMUNE HLDNGS LS-01 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.26 Million USD |
| MoneyControl | $1.26 Million USD |
| MarketWatch | $1.26 Million USD |
| marketcap.company | $1.26 Million USD |
| Reuters | $1.26 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.